Chromogranin a in monitoring response and prognosis of hormone refractory prostate cancer

By Lapini A.   Meliani E.   Semi S.   Masieri L.   Farina U.   Corvino C.   Carini M.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 189-189

Elsevier

Access to resources Recommend Favorite

Differential effect of chromogranin A fragments on invasion and growth of prostate cancer cells in vitro

By Nagakawa O.   Fujiuchi Y.   Fuse H.   Saiki I.  

Urology, Vol. 62, Iss. 3, 2003-09 ,pp. : 553-558

Elsevier

Access to resources Recommend Favorite

A combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and reduces chromogranin a (CGA) levels in androgen ablation-refractory prostate cancer patients

By Sciarra A.   Pastore A.   Voria G.   Cardi A.   Di Silverio F.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 187-187

Elsevier

Access to resources Recommend Favorite

Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer

By Kohli M.   Kaushal V.   Spencer H.J.   Mehta P.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 765-769

Elsevier

Access to resources Recommend Favorite

Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status

By Moreno J.G.   O'Hara S.M.   Gross S.   Doyle G.   Fritsche H.   Gomella L.G.   Terstappen L.W.M.M.  

Urology, Vol. 58, Iss. 3, 2001-09 ,pp. : 386-392

Elsevier

Access to resources Recommend Favorite